tirzepatide is a dual GIP/GLP-1 agonist) and their side effect profiles differ
Medication interactions matter too, especially with drugs like insulin or blood thinners
OIS acts as a safeguard against the development of cancer by halting the growth of potentially malignant cells.14 In other words, oncogenic activation (eg, RAS, RAF, and MYC) can induce senescence as a protective mechanism against uncontrolled proliferation
Poster Session II - PRE-HOSPITAL SERVICE ORGANISATION 09.00 - PRE-HOSPITAL SERVICE ORGANISATION - 09.01 - PRE-HOSPITAL SERVICE ORGANISATION P797 - ESOC25-1744 CO-DESIGN OF A MOBILE STROKE UNIT PATHWAY HIGHLIGHTS UNCERTAINTIES AND TRADE-OFFS FOR VIABLE SYSTEM-WIDE IMPLEMENTATION IN THE ENGLISH AND WELSH NHS Jason Scott 1 , Lisa Moseley 2 , Michael Allen 3 , Gary Ford 4 , Martin James 3 , Anna Laws 3 , Stephen McCarthy 1 , Graham McClelland 1 , Kerry Pearn 3 , Daniel Phillips 5 , Chris Price 2 , Lisa Shaw 2 , Philip White 2 , Dave Wilson 6 , Peter McMeekin 1 1 Northumbria University, Newcastle upon Tyne, United Kingdom, 2 Newcastle University, Newcastle upon Tyne, United Kingdom, 3 University of Exeter, Exeter, United Kingdom, 4 University of Oxford, Oxford, United Kingdom, 5 East of England Ambulance Service NHS Trust, Melbourn, United Kingdom, 6 Stroke Service User Voice Group, Newcastle upon Tyne, United Kingdom Background and Aims: Benefits of Mobile Stroke Units (MSUs) have been demonstrated but are context dependent
